{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T02:14:18Z","timestamp":1771640058377,"version":"3.50.1"},"reference-count":13,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1097\/dad.0000000000000231","type":"journal-article","created":{"date-parts":[[2014,10,30]],"date-time":"2014-10-30T11:52:53Z","timestamp":1414669973000},"page":"440-443","source":"Crossref","is-referenced-by-count":10,"title":["Primary Cutaneous Small\/Medium CD4+ T-Cell Lymphoma Occurring During Treatment With Vemurafenib for Advanced Melanoma"],"prefix":"10.1097","volume":"37","author":[{"given":"Maria C.","family":"Garrido","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erica","family":"Riveiro-Falkenbach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yolanda","family":"Ruano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo","family":"Ortiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose L.","family":"Rodriguez-Peralto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-2-20210202","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1056\/NEJMoa1112302","article-title":". Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.","volume":"366","author":"Sosman","year":"2012","journal-title":"N Engl J Med"},{"key":"R2-2-20210202","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1200\/JCO.1999.17.9.2745","article-title":". Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma.","volume":"17","author":"Chapman","year":"1999","journal-title":"J Clin Oncol"},{"key":"R3-2-20210202","doi-asserted-by":"crossref","first-page":"5748","DOI":"10.1200\/JCO.2008.17.5448","article-title":". Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group.","volume":"26","author":"Atkins","year":"2008","journal-title":"J Clin Oncol"},{"key":"R4-2-20210202","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":". Improved survival with ipilimumab in patients with metastatic melanoma.","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"R5-2-20210202","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":". Mutations of the BRAF gene in human cancer.","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"R6-2-20210202","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":". Improved survival with vemurafenib in melanoma with BRAF V600E mutation.","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"key":"R7-2-20210202","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1056\/NEJMoa1210093","article-title":". Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.","volume":"367","author":"Flaherty","year":"2012","journal-title":"N Engl J Med"},{"key":"R8-2-20210202","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1002011","article-title":". Inhibition of mutated, activated BRAF in metastatic melanoma.","volume":"363","author":"Flaherty","year":"2010","journal-title":"N Engl J Med"},{"key":"R9-2-20210202","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/bjd.12010","article-title":". Cutaneous adverse events associated with vemurafenib in patients with metastatic melanoma: practical advice on diagnosis, prevention and management of the main treatment-related skin toxicities.","volume":"167","author":"Sinha","year":"2012","journal-title":"Br J Dermatol"},{"key":"R10-2-20210202","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1200\/JCO.2011.41.1660","article-title":". Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition.","volume":"30","author":"Zimmer","year":"2012","journal-title":"J Clin Oncol"},{"key":"R11-2-20210202","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/DAD.0b013e31819f19bb","article-title":". Primary cutaneous CD4 small-medium-sized pleomorphic T-cell lymphoma: a cutaneous nodular proliferation of pleomorphic T lymphocytes of undetermined significance A study of 136 cases.","volume":"31","author":"Beltraminelli","year":"2009","journal-title":"Am J Dermatopathol"},{"key":"R12-2-20210202","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1158\/1078-0432.CCR-11-2479","article-title":". Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma.","volume":"18","author":"Wilmott","year":"2012","journal-title":"Clin Cancer Res"},{"key":"R13-2-20210202","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1002\/ijc.28168","article-title":". Vemurafenib reverses immunosuppression by myeloid derived suppressor cells.","volume":"133","author":"Schilling","year":"2013","journal-title":"Int J Cancer"}],"container-title":["The American Journal of Dermatopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/DAD.0000000000000231","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:00:03Z","timestamp":1620950403000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00000372-201506000-00002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":13,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1097\/dad.0000000000000231","relation":{},"ISSN":["0193-1091"],"issn-type":[{"value":"0193-1091","type":"print"}],"subject":[],"published":{"date-parts":[[2015,6]]}}}